Literature DB >> 17206635

Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis.

Fady Daniel1, Marie-Anne Loriot, Philippe Seksik, Jacques Cosnes, Jean-Marc Gornet, Marc Lémann, Francine Fein, Gwenola Vernier-Massouille, Martine De Vos, Arnaud Boureille, Xavier Treton, Bernard Flourié, Xavier Roblin, Edouard Louis, Frank Zerbib, Philippe Beaune, Philippe Marteau.   

Abstract

BACKGROUND: Cyclosporine A (CsA) is inconstantly effective in inducing remission in acute attacks of ulcerative colitis (UC) not responding to steroids. This study aimed to establish whether multidrug resistance gene (MDR)1 polymorphisms would be associated with CsA failure. PATIENTS AND METHODS: The distribution of the different genotypes of single nucleotide polymorphisms (SNP) G2677T/A and C3435T of MDR1 exons 21 and 26, respectively, was studied in 154 patients (mean age, 44 yr) who had received CsA to treat severe attacks of steroid resistant UC in 11 centers in France and Belgium. Patients were classified as CsA failure (n = 50) when they needed colectomy within 30 days after CsA initiation. The SNPs were detected by use of a 5' nuclease allelic discrimination assay.
RESULTS: There was a significant association between the G2677T/A polymorphism distribution (exon 21) and the risk for CsA failure (P = 0.0001). The TT genotype of exon 21 was significantly associated with the risk compared with the two other genotypes (odds ratio, 3.77; 95% confidence interval, 1.42-9.97, P = 0.007). There was no significant association between the genotype C3435T distribution (exon 26) and the risk of CsA failure (P = 0.23).
CONCLUSION: The TT genotype of exon 21 MDR1 polymorphisms is associated with a higher risk of CsA failure in patients with steroid resistant UC. Further studies should be performed to establish whether other treatments could be more efficient to avoid surgery in this subset of patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17206635     DOI: 10.1002/ibd.20046

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  13 in total

Review 1.  The role of pharmacogenetics in nonmalignant gastrointestinal diseases.

Authors:  Michael Camilleri
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-07       Impact factor: 46.802

2.  Current and future role of serogenomics in ulcerative colitis.

Authors:  Mark H Flasar; Raymond K Cross; David B Doman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-11

3.  Pharmacogenomics of IBD Therapies.

Authors:  Themistocles Dassopoulos
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-05

Review 4.  Crucial steps in the natural history of inflammatory bowel disease.

Authors:  Giovanni Latella; Claudio Papi
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

5.  Contribution of susceptibility variants at FCGR2A and 13q12 to the risk of relapse among Japanese patients with ulcerative colitis.

Authors:  Kouichi Asano; Motohiro Esaki; Junji Umeno; Atsushi Hirano; Yuji Maehata; Tomohiko Moriyama; Shotaro Nakamura; Takayuki Matsumoto; Takanari Kitazono
Journal:  J Gastroenterol       Date:  2015-03-19       Impact factor: 7.527

Review 6.  Acute severe ulcerative colitis: from pathophysiology to clinical management.

Authors:  Pieter Hindryckx; Vipul Jairath; Geert D'Haens
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-01       Impact factor: 46.802

7.  Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein).

Authors:  Laura M Hodges; Svetlana M Markova; Leslie W Chinn; Jason M Gow; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-03       Impact factor: 2.089

Review 8.  Clinical, serological and genetic predictors of inflammatory bowel disease course.

Authors:  Laurent Beaugerie; Harry Sokol
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

Review 9.  Value of colonoscopy for prediction of prognosis in patients with ulcerative colitis.

Authors:  Takafumi Ando; Yuji Nishio; Osamu Watanabe; Hironao Takahashi; Osamu Maeda; Kazuhiro Ishiguro; Daisuke Ishikawa; Naoki Ohmiya; Yasumasa Niwa; Hidemi Goto
Journal:  World J Gastroenterol       Date:  2008-04-14       Impact factor: 5.742

Review 10.  Steroid-refractory severe ulcerative colitis: what are the available treatment options?

Authors:  Alan C Moss; Mark A Peppercorn
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.